Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician’s perspective
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Several studies have provided ample evidence of a clinically significant interobserver variation of the histological diagnosis of glioma. This interobserver variation has an effect on both the typing and grading of glial tumors. Since treatment decisions are based on histological diagnosis and grading, this affects patient care: erroneous classification and grading may result in both over- and undertreatment. In particular, the radiotherapy dosage and the use of chemotherapy are affected by tumor grade and lineage. It also affects the conduct and interpretation of clinical trials on glioma, in particular of studies into grade II and grade III gliomas. Although trials with central pathology review prior to inclusion will result in a more homogeneous patient population, the interpretation and external validity of such trials are still affected by this, and the question whether results of such trials can be generalized to patients diagnosed and treated elsewhere remains to be answered. Although molecular classification may help in typing and grading tumors, as of today this is still in its infancy and unlikely to completely replace histological classification. Routine pathology review in everyday clinical practice should be considered. More objective histological criteria for the grade and lineage of gliomas are urgently needed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Histologic diagnosis and grading of gliomas have been limited by considerable intra- and interobserver variability (42).”
From Predicting cancer outcomes from histology and genomics using convolutional networks (2018) · cites this paper as [42]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, the grading criteria in the current classification schema for oligodendrogliomas continues to predominantly rely upon histopathologic examination; the differentiating criterion between grade 2 and grade 3 oligodendrogliomas are the presence of conspicuous microvascular proliferation and/or 6 mitoses per 10 high-power field [3,4,5,6,7,8,9,10,11].”
From BPC 157 Therapy of Myotendinous Junction Injury in Rats (2025) · cites this paper as [9]
Experimental — accuracy not yet measuredIn the citing paper
“Importantly, these data further facilitate consensus ratings on radiology images (e.g., MRI) of expert radiologists to alleviate inconsistencies that often arise due to subjective impressions and inter- and intra-observer variability [229].”
From AI in Medical Imaging Informatics: Current Challenges and Future Directions (2020) · cites this paper as [229]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The 2007 WHO Classification of Tumours of the Central Nervous System
Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K., Burger, P. C., Jouvet, A., Scheithauer, B. W., & Kleihues, P. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0243-4 · Cited by 15,397
External validity of randomised controlled trials: “To whom do the results of this trial apply?”
Rothwell, P. M. (2005) · The Lancet · doi:10.1016/s0140-6736(04)17670-8 · Cited by 2,544 · cited 1×
“This issue is on the question of external validation or generalizability of the results of a trial, an often ignored element of clinical trials [26].”
BackgroundCairncross, J. G., Ueki, K., Zlatescu, M. C., Lisle, D. K., Finkelstein, D. M., Hammond, R. R., Silver, J. S., Stark, P. C., Macdonald, D. R., Ino, Y., et al. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.19.1473 · Cited by 1,610
Feinstein, A. R., Sosin, D. M., & Wells, C. K. (1985) · New England Journal of Medicine · doi:10.1056/nejm198506203122504 · Cited by 1,544
An analysis of 8305 cases of carcinoid tumors
Modlin, I. M., & Sandor, A. (2000) · Cancer · doi:10.1002/(sici)1097-0142(19970215)79:4<813::aid-cncr19>3.0.co;2-2 · Cited by 1,200
Nutt, C. L., Mani, D. R., Betensky, R. A., Tamayo, P., Cairncross, J. G., Ladd, C., Pohl, U., Hartmann, C. J., McLaughlin, M. E., Batchelor, T. T., et al. (2003) · PubMed · Cited by 1,058
van den Bent, M., Afra, D., de Witte, O., Hassel, M. B., Schraub, S., Hoang-Xuan, K., Malmström, P.-O., Collette, L., Piérart, M., Mirimanoff, R., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67070-5 · Cited by 1,035
Wick, W., Hartmann, C., Engel, C., Stoffels, M., Felsberg, J., Stockhammer, F., Sabel, M. C., Koeppen, S., Ketter, R., Meyermann, R., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.6497 · Cited by 809
Smith, J. S., Perry, A., Borell, T. J., Lee, H. K., O’Fallon, J., Hosek, S. M., Kimmel, D., Yates, A., Burger, P. C., Scheithauer, B. W., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.3.636 · Cited by 804
van den Bent, M. J., Carpentier, A. F., Brandes, A. A., Sanson, M., Taphoorn, M. J. B., Bernsen, H. J. J. A., Frenay, M., Tijssen, C. C., Grisold, W., Sipos, L., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.6078 · Cited by 748
Research works printed but not linked: 1
- Coons SW, Johnson PC, Scheithauer BW, Yates AJ, Pearl DK (1997) Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer 79:1381–1391 · doi:10.1002/(sici)1097-0142(19970401)79:7<1381::aid-cncr16>3.0.co;2-w
Cited by
Items 201–300 of 640
Complications from radiotherapy
Dhermain, F. G., & Barani, I. J. (2016) · Handbook of clinical neurology · doi:10.1016/b978-0-12-802997-8.00013-x · Cited by 35
Prognostic risk stratification of gliomas using deep learning in digital pathology images
Chunduru, P., Phillips, J. J., & Molinaro, A. M. (2022) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdac111 · Cited by 34
MALDI imaging and in‐source decay for top‐down characterization of glioblastoma
Ait-Belkacem, R., Berenguer‐Daizé, C., Villard, C., Ouafik, L., Figarella‐Branger, D., Chinot, O. L., & Lafitte, D. (2014) · PROTEOMICS · doi:10.1002/pmic.201300329 · Cited by 34
Disparities in Brain Cancer in the United States: A Literature Review of Gliomas
Persaud-Sharma, D., Burns, J., Trangle, J., & Moulik, S. (2017) · Medical Sciences · doi:10.3390/medsci5030016 · Cited by 34
Recurrent ubiquitin B silencing in gynecological cancers establishes dependence on ubiquitin C
Kedves, A. T., Gleim, S., Liang, X., Bonal, D. M., Sigoillot, F. D., Harbinski, F., Sanghavi, S., Benander, C., George, E., Gokhale, P. C., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci92914 · Cited by 34
Han, Y., Wang, W., Yang, Y., Sun, Y., Xiao, G., Tian, Q., Zhang, J., Cui, G., & Yan, L. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00144 · Cited by 33
Low-Grade Gliomas: Histological Subtypes, Molecular Mechanisms, and Treatment Strategies
Toader, C., Eva, L., Costea, D., Corlatescu, A.-D., Covache-Busuioc, R.-A., Bratu, B.-G., Glavan, L.-A., Costin, H. P., Popa, A. A., & Ciurea, A. V. (2023) · Brain Sciences · doi:10.3390/brainsci13121700 · Cited by 33
Shibui, S., Narita, Y., Mizusawa, J., Beppu, T., Ogasawara, K., Sawamura, Y., Kobayashi, H., Nishikawa, R., Mishima, K., Muragaki, Y., et al. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-2041-5 · Cited by 33
Zhang, F., Liu, Y., Zhang, Z., Li, J., Wan, Y., Zhang, L., Wang, Y., Li, X., Xu, Y., Fu, X., et al. (2016) · Scientific Reports · doi:10.1038/srep20882 · Cited by 33
Kani, Y., Cecere, T. E., Lahmers, K. K., LeRoith, T., Zimmerman, K., Isom, S. P., Hsu, F., Debinksi, W., Robertson, J. L., & Rossmeisl, J. H. (2019) · Journal of Veterinary Internal Medicine · doi:10.1111/jvim.15500 · Cited by 33
Microvascularity detection and quantification in glioma: a novel deep-learning-based framework
Li, X., Tang, Q., Yu, J., Wang, Y., & Shi, Z. (2019) · Laboratory Investigation · doi:10.1038/s41374-019-0272-3 · Cited by 33
Joyner, D., Garrett, J., Batchala, P. P., Rama, B., Ravicz, J. R., Patrie, J. T., Lopes, M.-B., Fadul, C. E., Schiff, D., Jain, R., et al. (2022) · Neuroradiology · doi:10.1007/s00234-022-03038-0 · Cited by 32
Luo, C., Yang, J., Liu, Z., & Jing, D. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1100933 · Cited by 32
Jakola, A. S., Unsgård, G., Myrmel, K. S., Kloster, R., TORP, S. H., Losvik, O. K., Lindal, S., & Solheim, O. S. (2013) · Acta Neurochirurgica · doi:10.1007/s00701-013-1869-8 · Cited by 32
Adjudication Rates between Readers in Blinded Independent Central Review of Oncology Studies
O, F. R., & Neal, M. (2016) · Journal of Clinical Trials · doi:10.4172/2167-0870.1000289 · Cited by 32
van der Vaart, T., Wijnenga, M. M. J., van Garderen, K. A., Dubbink, H. J., French, P. J., Smits, M., Dirven, C. M. F., Kros, J. M., Vincent, A. J. P. E., & van den Bent, M. J. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-0901 · Cited by 31
Artificial intelligence in neuro-oncology
Nakhate, V., & Castro, L. N. G. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1217629 · Cited by 31
Acharya, S., Liu, J., Tatevossian, R., Chiang, J., Qaddoumi, I. A., Gajjar, A. J., Walker, D. A., Harreld, J. H., Merchant, T. E., & Ellison, D. W. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa031 · Cited by 30
Domain Knowledge Based Brain Tumor Segmentation and Overall Survival Prediction
Guo, X., Yang, C., Lam, P. L., Woo, P. Y., & Yuan, Y. (2020) · Lecture notes in computer science · doi:10.1007/978-3-030-46643-5_28 · Cited by 30
Further understanding of the pathology of glioma: implications for the clinic
Camelo-Piragua, S. I., & Kesari, S. (2016) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2016.1194755 · Cited by 30
Lee, D. M., Riestenberg, R. A., Haskell-Mendoza, A. P., & Bloch, O. G. (2021) · Journal of Neuro-Oncology · doi:10.1007/s11060-020-03677-4 · Cited by 30
Anaplastic Astrocytoma: State of the art and future directions
Caccese, M., Padovan, M., D’Avella, D., Chioffi, F., Gardiman, M. P., Berti, F., Busato, F., Bellu, L., Bergo, E., Zoccarato, M., et al. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103062 · Cited by 29
Combining Radiology and Pathology for Automatic Glioma Classification
Wang, X., Wang, R., Yang, S., Zhang, J., Wang, M., Zhong, D., Zhang, J., & Han, X. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.841958 · Cited by 29
Integrative multi-omics approach to targeted therapy for glioblastoma
Koh, L., Novera, W., Lim, S. W., Chong, Y. K., Pang, Q. Y., Low, D. C. Y., Ang, B. T., & Tang, C. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106308 · Cited by 29
Treatment of Adult Lower-Grade Glioma in the Era of Genomic Medicine
Chang, S. M., Cahill, D. P., Aldape, K., & Mehta, M. P. (2016) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_158869 · Cited by 29
Outcomes and Prognostic Factors in Pediatric Oligodendroglioma: A Population-Based Study
Goel, N. J., Abdullah, K. G., & Lang, S. (2017) · Pediatric Neurosurgery · doi:10.1159/000481458 · Cited by 29
Methylation Profiling in Diffuse Gliomas: Diagnostic Value and Considerations
Wenger, A., & Carén, H. (2022) · Cancers · doi:10.3390/cancers14225679 · Cited by 28
Djuric, U., Lam, K. H. B., Kao, J., Batruch, I., Jevtic, S. D., Papaioannou, M.-D., & Diamandis, P. (2019) · Molecular & Cellular Proteomics · doi:10.1074/mcp.ra119.001521 · Cited by 28
Current Management of Adult Diffuse Infiltrative Low Grade Gliomas
Rhun, É. L., Taillibert, S., & Chamberlain, M. C. (2016) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-015-0615-4 · Cited by 27
Lee, A., Youssef, I., Osborn, V. W., Safdieh, J. J., Becker, D. J., & Schreiber, D. P. (2018) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2018.02.009 · Cited by 27
Prognostic model and nomogram construction based on autophagy signatures in lower grade glioma
Wang, C., Qiu, J., Chen, S., Li, Y., Hu, H., Cai, Y., & Hou, L.-J. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.29837 · Cited by 27
A Deep Learning–Based Framework for Supporting Clinical Diagnosis of Glioblastoma Subtypes
Munquad, S., Si, T., Mallik, S., Das, A. B., & Zhao, Z. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.855420 · Cited by 27
Preclinical and Clinical Applications of Metabolomics and Proteomics in Glioblastoma Research
Ahmed, M., Semreen, A. M., El‐Huneidi, W., Bustanji, Y. K., Abu‐Gharbieh, E., Alqudah, M. A. Y., Alhusban, A., Shara, M., Abuhelwa, A. Y., Soares, N. C., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010348 · Cited by 28
A computer-aided diagnosis system for brain tumors based on artificial intelligence algorithms
Chen, T., Hu, L., Lu, Q., Xiao, F., Xu, H., Li, H., & Lu, L. J. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1120781 · Cited by 27
Context aware machine learning techniques for brain tumor classification and detection – A review
Amjad, U., Raza, A., Fahad, M., Farid, D., Akhunzada, A., Abubakar, M., & Beenish, H. (2025) · Heliyon · doi:10.1016/j.heliyon.2025.e41835 · Cited by 27
Rusthoven, C. G., Carlson, J. A., Waxweiler, T. V., Dally, M. J., Barón, A. E., Yeh, N., Gaspar, L. E., Liu, A. K., Ney, D. E., Damek, D. M., et al. (2014) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2014.07.046 · Cited by 27
Natural History of Pediatric Low-Grade Glioma Disease - First Multi-State Model Analysis
Goebel, A.-M., Gnekow, A. K., Kandels, D., Witt, O., Schmidt, R., & Driever, P. H. (2019) · Journal of Cancer · doi:10.7150/jca.33463 · Cited by 27
Du, N., Shu, W., Li, K., Deng, Y., Xu, X., Yao, Y., Tang, F. R., Mao, R., Lin, G., Li, S., et al. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-03950-w · Cited by 26
State of the Art in Low-Grade Glioma Management: Insights From Isocitrate Dehydrogenase and Beyond
Schaff, L. R., Ioannou, M., Geurts, M., van den Bent, M. J., Mellinghoff, I. K., & Schreck, K. C. (2024) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_431450 · Cited by 26
Rajmohan, K., Sugur, H. S., Shwetha, S. D., Ramesh, A. V., Thennarasu, K., Pandey, P., Arivazhagan, A., & Santosh, V. (2016) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2015-203456 · Cited by 26
Automated Classification and Segmentation in Colorectal Images Based on Self‐Paced Transfer Network
Yao, Y., Gou, S., Ru, T., Zhang, X., & He, S. (2021) · BioMed Research International · doi:10.1155/2021/6683931 · Cited by 26
Yang, Z., Feng, L., Ruan, S., Hu, J., Tang, M., Sun, X., & Long, W. (2021) · Cancer Management and Research · doi:10.2147/cmar.s336213 · Cited by 26
The renal v‐ATPase a4 subunit is expressed in specific subtypes of human gliomas
Gleize, V., Boisselier, B., Marie, Y., Poëa‐Guyon, S., Sanson, M., & Morel, N. (2012) · Glia · doi:10.1002/glia.22332 · Cited by 26
Kümmel, T., van Marwick, B., Rittel, M. F., Guevara, C. R., Wühler, F., Teumer, T., Wängler, B., Hopf, C., & Rädle, M. (2021) · Scientific Reports · doi:10.1038/s41598-021-90777-4 · Cited by 25
Cornelli, L., Paemel, R. V., dos Santos, M. R. F., Roelandt, S., Willems, L., Vandersteene, J., Baert, E. J., Mus, L. M., Roy, N. V., Wilde, B. D., et al. (2024) · Clinical Epigenetics · doi:10.1186/s13148-024-01696-w · Cited by 25
McDonald, K. L., Aw, G., & Kleihues, P. (2013) · Frontiers in Neurology · doi:10.3389/fneur.2012.00188 · Cited by 25
World Health Organization grade II – III astrocytomas consist of genetically distinct tumor lineages
Hattori, N., Hirose, Y., Sasaki, H., Nakae, S., Hayashi, S., Ohba, S., Adachi, K., Hayashi, T., Nishiyama, Y., Hasegawa, M., et al. (2016) · Cancer Science · doi:10.1111/cas.12969 · Cited by 25
IDH mutation status trumps the Pignatti risk score as a prognostic marker in low-grade gliomas
Etxániz, O., Carrato, C., de Aguirre, I., Queralt, C., Muñoz-Mármol, A. M., Ramírez, J. L., Rosell, R., Villà, S., Díaz, R. L., Estival, A., et al. (2017) · Journal of Neuro-Oncology · doi:10.1007/s11060-017-2570-1 · Cited by 25
Vollmuth, P., Karschnia, P., Sahm, F., Park, Y. W., Ahn, S. S., & Jain, R. (2025) · Korean Journal of Radiology · doi:10.3348/kjr.2024.0982 · Cited by 24
Jim, J. R., Rayed, M. E., Mridha, M. F., & Nur, K. M. (2025) · PLoS ONE · doi:10.1371/journal.pone.0322488 · Cited by 24
Clinical utility of a blood based assay for the detection of IDH1.R132H-mutant gliomas
Batool, S. M., Escobedo, A. K., Hsia, T., Ekanayake, E., Khanna, S. K., Gamblin, A. S., Zheng, H., Skog, J., Miller, J. J., Stemmer-Rachamimov, A. O., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51332-7 · Cited by 24
Zhang, C., & Brat, D. J. (2016) · 癌症:英文版 · doi:10.1186/s40880-015-0071-1 · Cited by 24
Schiera, G., Liegro, C. M. D., & Liegro, I. D. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18122774 · Cited by 24
Prognostic factors associated with survival in patients with anaplastic oligodendroglioma
Liu, S., Liu, X., Xiao, Y., Chen, S., & Zhuang, W. (2019) · PLoS ONE · doi:10.1371/journal.pone.0211513 · Cited by 24
Role of molecular biomarkers in glioma resection: a systematic review
Li, L., Wang, Y., Li, Y., Fang, S., & Jiang, T. (2020) · Chinese Neurosurgical Journal · doi:10.1186/s41016-020-00198-x · Cited by 25
CAMKK2, Regulated by Promoter Methylation, is a Prognostic Marker in Diffuse Gliomas
Liu, D., Wang, H., Han, B. R., Meng, X., Chen, M., Yang, D., Sun, Y., Li, Y., & Jiang, C. (2016) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12531 · Cited by 24
Wang, X., Shan, C., Deng, X., Li, L., & Ma, W. (2017) · Oncology Reports · doi:10.3892/or.2017.5986 · Cited by 24
The Role of Mutant IDH Inhibitors in the Treatment of Glioma
Nakhate, V., Lasica, A. B., & Wen, P. Y. (2024) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-024-01378-3 · Cited by 23
Hu, W., Wang, F., Xi, S., Zhang, X., Lai, J., Wu, H.-Y., Liu, L., Sai, K., & Zeng, J. (2020) · Journal of Cancer · doi:10.7150/jca.38603 · Cited by 23
miR‑124‑3p inhibits the viability and motility of glioblastoma multiforme by targeting RhoG
Cai, S., Shi, C.-J., Lu, J.-X., Wang, Y.-P., Tian, Y., & Wang, X. (2021) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2021.4902 · Cited by 23
RetractedLauber, C., Klink, B., & Seifert, M. (2018) · BMC Cancer · doi:10.1186/s12885-018-4251-7 · Cited by 23
Xiao, Y., Cui, G., Ren, X., Hao, J., Zhang, Y., Yang, X., Wang, Z., Zhu, X., Wang, H., Hao, C., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.605737 · Cited by 22
Ketogenic diet as a treatment and prevention strategy for cancer: A therapeutic alternative
Neha, N., & Chaudhary, R. (2024) · Nutrition · doi:10.1016/j.nut.2024.112427 · Cited by 22
Ghisai, S. A., van Hijfte, L., Vallentgoed, W., Tesileanu, C. M. S., de Heer, I. J., Kros, J. M., Sanson, M., Gorlia, T., Wick, W., Vogelbaum, M. A., et al. (2024) · Acta Neuropathologica · doi:10.1007/s00401-024-02811-0 · Cited by 23
Radiomic profiles in diffuse glioma reveal distinct subtypes with prognostic value
Lin, P., Peng, Y., Gao, R., Yan, W., Li, X., Huang, S.-N., Fang, Y., Wei, Z., Huang, Z., Yang, H., et al. (2020) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03153-6 · Cited by 22
Sonoda, Y. (2020) · International Journal of Clinical Oncology · doi:10.1007/s10147-020-01628-7 · Cited by 22
Controversies in the Therapy of Low-Grade Gliomas
Carabenciov, I. D., & Buckner, J. C. (2019) · Current Treatment Options in Oncology · doi:10.1007/s11864-019-0625-6 · Cited by 21
Mair, M. J., Leibetseder, A., Heller, G., Puhr, R., Tomasich, E., Goldberger, S., Hatziioannou, T., Wöhrer, A., Widhalm, G., Dieckmann, K. U., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1133 · Cited by 21
Recent advances in the molecular prognostication of meningiomas
Wang, E. J., Haddad, A. F., Young, J. S., Morshed, R. A., Wu, J. P. H., Salha, D. M., Butowski, N. A., & Aghi, M. K. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.910199 · Cited by 21
Tan, Y., Liu, R., Xue, J., & Feng, Z. (2024) · Cancer Medicine · doi:10.1002/cam4.6947 · Cited by 22
Overview and recent advances in neuropathology. Part 1: Central nervous system tumours
Robertson, T., Koszyca, B., & Gonzales, M. F. (2011) · Pathology · doi:10.1097/pat.0b013e3283426e86 · Cited by 21
Conventional MR-based Preoperative Nomograms for Prediction of IDH/1p19q Subtype in Low-Grade Glioma
Liu, Z., Zhang, T., Jiang, H., Xu, W., & Zhang, J. (2018) · Academic Radiology · doi:10.1016/j.acra.2018.09.022 · Cited by 21
Albert, N. L., Furtner, J., van den Bent, M. J., & Preusser, M. (2023) · Neuro-Oncology · doi:10.1093/neuonc/noad240 · Cited by 19
Yang, J., Shen, L., Yang, J., Qu, Y., Gong, C., Zhou, F., Liu, Y., Luo, M., & Zhao, L. (2024) · Translational Cancer Research · doi:10.21037/tcr-23-906 · Cited by 19
Strowd, R. E., III, Abuali, I. A., Ye, X., Lu, Y., & Grossman, S. A. (2016) · Journal of Neuro-Oncology · doi:10.1007/s11060-015-2028-2 · Cited by 19
Contemporary management of low-grade glioma: a paradigm shift in neuro-oncology
Hayhurst, C. (2017) · Practical Neurology · doi:10.1136/practneurol-2017-001604 · Cited by 19
EGFRAmplification andIDHMutations in Glioblastoma Patients of the Northeast of Morocco
Senhaji, N., Louati, S., Chbani, L., Fatemi, H. E., Hammas, N., Mikou, K., Maâroufi, M., Benzagmout, M., Boujraf, S., Bardai, S. E., et al. (2017) · BioMed Research International · doi:10.1155/2017/8045859 · Cited by 20
Malignant clinical features of anaplastic gliomas without IDH mutation
Shibahara, I., Sonoda, Y., Shoji, T., Kanamori, M., Saito, R., Inoue, T., Kawaguchi, T., Yamashita, Y., Watanabe, T., Kumabe, T., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou112 · Cited by 19
Anaplastic Oligodendroglioma: A New Treatment Paradigm and Current Controversies
Roth, P., Wick, W., & Weller, M. (2013) · Current Treatment Options in Oncology · doi:10.1007/s11864-013-0251-7 · Cited by 19
Deep Learning Models for Digital PathologyPreprint
BenTaieb, A., & Hamarneh, G. (2019) · arXiv (Cornell University) · doi:10.48550/arxiv.1910.12329 · Cited by 21
Mitosin and pHH3 predict poorer survival in astrocytomas WHO grades II and III
Varughese, R. K., Lind‐Landström, T., Habberstad, A. H., Salvesen, Ø. O., Haug, C., Sundstrøm, S. H., & TORP, S. H. (2015) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2015-202983 · Cited by 18
Deland, L., Keane, S., Bontell, T. O., Sjögren, H., Fagman, H., Øra, I., Cuesta, E. A. D. L., Tisell, M., Nilsson, J. A., Ejeskär, K., et al. (2021) · Cancer Biology & Therapy · doi:10.1080/15384047.2021.1899573 · Cited by 18
Wu, S., Xu, J., Li, G., & Jin, X. H. (2022) · Medicina · doi:10.3390/medicina58101327 · Cited by 17
Key genes altered in glioblastoma based on bioinformatics (Review)
Ghafari, M. A., Jaafari, N. E., Mouallem, M., Maassarani, T., El‐Sibai, M., & Abi‐Habib, R. J. (2025) · Oncology Letters · doi:10.3892/ol.2025.14989 · Cited by 17
Stålhammar, G., Yeung, A. M.-H., Mendoza, P. R., Dubovy, S. R., Harbour, J. W., & Grossniklaus, H. E. (2021) · Ophthalmology Science · doi:10.1016/j.xops.2021.100089 · Cited by 17
Suman, S., Sharma, R. S., Katiyar, V., Mahajan, S., Suri, A., Sharma, M. C., Sarkar, C., & Suri, V. S. (2022) · Neurosurgical FOCUS · doi:10.3171/2022.9.focus22427 · Cited by 17
Özer, E., Bilecen, A. E., Ozer, N. B., & Yanikoglu, B. A. (2022) · Cytopathology · doi:10.1111/cyt.13192 · Cited by 16
Radio-pathomic approaches in pediatric neuro-oncology: Opportunities and challenges
Familiar, A., Mahtabfar, A., Kazerooni, A. F., Kiani, M., Vossough, A., Viaene, A. N., Storm, P. B., Resnick, A. C., & Nabavizadeh, A. (2023) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdad119 · Cited by 16
Zhao, Y., Wang, W., Ji, Y., Guo, Y., Duan, J., Liu, X., Yan, D., Liang, D., Li, W., Zhang, Z., et al. (2024) · American Journal Of Pathology · doi:10.1016/j.ajpath.2024.01.009 · Cited by 16
Dee, W., Ibrahim, R. A., & Marouli, E. (2024) · PLoS ONE · doi:10.1371/journal.pone.0310417 · Cited by 16
GOBBO, A. D., Vaira, V., Ferrari, L., Patriarca, C., Cristofori, A. D., Ricca, D., Caroli, M., Rampini, P. M., Bòsari, S., & Ferrero, S. (2015) · BioMed Research International · doi:10.1155/2015/413897 · Cited by 16
Zhang, Z., Chan, A. K., Ding, X., Li, Y., Zhang, R., Chen, L., Liu, Y., Wang, Y., Xiong, J., Ng, H., et al. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox042 · Cited by 16
Riemenschneider, M. J., Louis, D. N., Weller, M., & Hau, P. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1127-4 · Cited by 16
Giannoni, L., Marradi, M., Scibilia, K., Ezhov, I., Bonaudo, C., Artemiou, A., Toaha, A., Lange, F., Caredda, C., Montcel, B., et al. (2024) · Journal of Biomedical Optics · doi:10.1117/1.jbo.29.9.093508 · Cited by 15
Prognostic value and their clinical implication of 89-gene signature in glioma
Shahid, M., Cho, K. M., Nguyen, M. N., Choi, T. G., Jo, Y. H., Aryal, S. N., Yoo, J. Y., Yun, H. R., Lee, J. W., Eun, Y., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9983 · Cited by 15
Wang, P., Luo, C., Hong, P., Rui, W., & Wu, S. (2021) · Neurosurgery · doi:10.1093/neuros/nyab052 · Cited by 15
Wehbe, K., Forfar, I., Eimer, S., & Cinque, G. (2015) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-015-8891-z · Cited by 15
Molecularly based management of gliomas in clinical practice
Rudà, R., Pellerino, A., Magistrello, M., Franchino, F., Pinessi, L., & Soffietti, R. (2015) · Neurological Sciences · doi:10.1007/s10072-015-2332-9 · Cited by 15
Significant heterogeneity in the geographical distribution of diffuse grade II/III gliomas in France
Darlix, A., Zouaoui, S., Virion, J., Rigau, V., Mathieu‐Daudé, H., Blonski, M., Reyes-Botero, G., Bessaoud, F., Trétarre, B., Bauchet, F., et al. (2014) · Journal of Neuro-Oncology · doi:10.1007/s11060-014-1585-0 · Cited by 17
Zhao, X., Zhan, Y., Bao, J.-J., Zhou, J., Zhang, F., Yu, B., Bai, Y., Wang, Y., Zhang, Z.-Y., & Liu, X. (2017) · Oncotarget · doi:10.18632/oncotarget.23371 · Cited by 15
Metadata
- Authors
- van den Bent, M. J.
- Venue
- Acta Neuropathologica
- Published
- 2010-07-20
- Volume
- 120
- Issue
- 3
- Pages
- 297-304
- ISSN
- 0001-6322 (ISSN-L)
- 1432-0533
- PMC
- PMC2910894
- OpenAlex
- W2112567075
- Cited by
- 577
- References
- 35
- Citations by year
- 2026: 19 · 2025: 36 · 2024: 70 · 2023: 43 · 2022: 43 · 2021: 47 · 2020: 48 · 2019: 52 · 2018: 33 · 2017: 46 · 2016: 44 · 2015: 33 · 2014: 16 · 2013: 16 · 2012: 20
- FWCI
- 6.54
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- Locations
- Acta Neuropathologica (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Social Sciences › Decision Sciences › Statistics, Probability and Uncertainty › Reliability and Agreement in Measurement
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiomics and Machine Learning in Medical Imaging
- Keywords
- glioma, interobserver variability, histopathological diagnosis, tumor grading, tumor classification, central pathology review, clinical trial interpretation, generalizability, molecular classification, chemotherapy
- MeSH terms
- Brain Neoplasms, Clinical Trials as Topic, Glioma, Humans, Observer Variation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.